← All trials
NCT05452005
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2022
- Primary completion
- May 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jul 11, 2022
- Last posted
- Sep 21, 2022
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, DavisLead sponsor
- Department of DefenseCollaborator
- University of California, DavisReponsible party - principal investigator
- University of California, DavisSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.